Cerebrospinal fluid concentrations of antituberculosis agents in adults and children

P R Donald1

  • 1Department of Paediatrics and Child Health and Division of Molecular Biology and Human Genetics and the MRC Centre for Molecular and Cellular Biology, DST/NRF Centre of Excellence for Biomedical TB Research, Faculty of Health Sciences, University of Stellenbosch and Tygerberg Children's Hospital, PO Box 19063, 7505 Tygerberg, South Africa. prd@sun.ac.za

Insights

Optimizing antituberculosis drug selection for tuberculous meningitis (TBM) is crucial. Isoniazid and pyrazinamide show good cerebrospinal fluid penetration, while others like streptomycin have poor penetration, impacting TBM treatment efficacy.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Neurology

Background:

  • Tuberculous meningitis (TBM) presents a significant global health challenge, causing severe morbidity and mortality in both children and adults.
  • Despite early diagnosis and treatment, patient outcomes can be poor due to inadequate drug penetration into the cerebrospinal fluid (CSF).

Purpose of the Study:

  • To review the literature on the cerebrospinal fluid (CSF) penetration of antituberculosis agents.
  • To guide optimal drug selection and dosing for tuberculous meningitis (TBM) treatment based on CSF pharmacokinetics.

Main Methods:

  • Systematic literature review of studies evaluating antituberculosis drug concentrations in CSF.
  • Analysis of pharmacokinetic data, including peak concentrations (Cmax) and their relation to minimum inhibitory concentrations (MIC).

Main Results:

  • Isoniazid demonstrates excellent CSF penetration. Pyrazinamide achieves therapeutic CSF concentrations, especially in children at recommended doses.
  • Streptomycin, ethambutol, and adult-dose rifampicin exhibit poor CSF penetration, limiting their use as first-line agents.
  • Non-essential agents like ethionamide, fluoroquinolones (except ciprofloxacin), and cycloserine show good CSF penetration and are recommended.

Conclusions:

  • Drug selection for TBM should prioritize agents with proven CSF penetration, such as isoniazid and pyrazinamide.
  • Dosage adjustments, particularly for rifampicin in children, are necessary to achieve effective CSF concentrations.
  • Prompt initiation of chemotherapy with appropriate agents is vital for improving TBM patient outcomes.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
338
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
289
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
656
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
557
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.0K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.1K